Provectus Biopharmaceuticals Company Profile (NYSEMKT:PVCT)

About Provectus Biopharmaceuticals (NYSEMKT:PVCT)

Provectus Biopharmaceuticals logoProvectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:PVCT
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.05
  • 200 Day Moving Avg: $0.03
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.0000
Misc:
  • Beta: 0.44
 

Frequently Asked Questions for Provectus Biopharmaceuticals (NYSEMKT:PVCT)

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PVCT."

Who are some of Provectus Biopharmaceuticals' key competitors?

How do I buy Provectus Biopharmaceuticals stock?

Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Provectus Biopharmaceuticals stock cost?

One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.83.

Analyst Ratings

Consensus Ratings for Provectus Biopharmaceuticals (NYSEMKT:PVCT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
Earnings by Quarter for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
Earnings History by Quarter for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q215($0.02)$1.08 millionViewN/AView Earnings Details
5/7/2015Q115($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Provectus Biopharmaceuticals (NYSEMKT:PVCT)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
Latest Headlines for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
Source:
DateHeadline
finance.yahoo.com logoProvectus Biopharmaceuticals Reestablishes Strategic Advisory Board
finance.yahoo.com - April 20 at 7:29 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Closes Definitive Financing With PRH Group
finance.yahoo.com - April 7 at 12:08 PM
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 31 at 7:34 PM
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disc
biz.yahoo.com - March 23 at 7:53 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment
finance.yahoo.com - March 23 at 7:53 PM
us.rd.yahoo.com logoProvectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus
us.rd.yahoo.com - March 6 at 8:43 AM
us.rd.yahoo.com logoProvectus Biopharmaceuticals Provides Information On Rights Offering Deadline
us.rd.yahoo.com - February 24 at 8:36 PM
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 15 at 12:01 AM
prnewswire.com logoProvectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering - PR Newswire (press release)
www.prnewswire.com - February 12 at 8:28 AM
finance.yahoo.com logoProvectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
finance.yahoo.com - February 10 at 9:47 PM
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modificat
biz.yahoo.com - February 8 at 9:37 PM
bizjournals.com logoHow These Drug Makers Stocks are Faring? -- Provectus Biopharma, TherapeuticsMD, Novartis, and Tonix Pharma
www.bizjournals.com - February 3 at 8:20 PM
seekingalpha.com logoProvectus commences rights offering to stockholders - Seeking Alpha
seekingalpha.com - February 1 at 10:11 PM
finance.yahoo.com logoProvectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants
finance.yahoo.com - January 31 at 9:19 PM
businesswire.com logoProvectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO - Business Wire (press release)
www.businesswire.com - December 31 at 12:46 AM

Social

This page was last updated on 5/27/2017 by MarketBeat.com Staff